Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BLM-07D1 by Systimmune for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According to...
Danvilostomig by Systimmune for Nasopharyngeal Cancer: Likelihood of Approval
Danvilostomig is under clinical development by Systimmune and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II...
Izalontamab by Systimmune for Nasopharyngeal Cancer: Likelihood of Approval
Izalontamab is under clinical development by Systimmune and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...
Izalontamab by Systimmune for Laryngeal Cancer: Likelihood of Approval
Izalontamab is under clinical development by Systimmune and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Izalontamab by Systimmune for Hypopharyngeal Cancer: Likelihood of Approval
Izalontamab is under clinical development by Systimmune and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
Izalontamab by Systimmune for Colon Cancer: Likelihood of Approval
Izalontamab is under clinical development by Systimmune and currently in Phase I for Colon Cancer. According to GlobalData, Phase I...
BLB-01D1 by Systimmune for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
BLB-01D1 is under clinical development by Systimmune and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According to...
GNC-035 by Systimmune for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GNC-035 is under clinical development by Systimmune and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
GNC-035 by Systimmune for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GNC-035 is under clinical development by Systimmune and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
Emfizatamab by Systimmune for Secondary CNS Lymphoma: Likelihood of Approval
Emfizatamab is under clinical development by Systimmune and currently in Phase II for Secondary CNS Lymphoma. According to GlobalData, Phase...
Emfizatamab by Systimmune for Primary CNS Lymphoma: Likelihood of Approval
Emfizatamab is under clinical development by Systimmune and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...
Danvilostomig by Systimmune for Peritoneal Cancer: Likelihood of Approval
Danvilostomig is under clinical development by Systimmune and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
BLM-02D1 by Systimmune for Solid Tumor: Likelihood of Approval
BLM-02D1 is under clinical development by Systimmune and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Danvilostomig by Systimmune for Fallopian Tube Cancer: Likelihood of Approval
Danvilostomig is under clinical development by Systimmune and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
Danvilostomig by Systimmune for Endometrial Cancer: Likelihood of Approval
Danvilostomig is under clinical development by Systimmune and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
GNC-039 by Systimmune for Solid Tumor: Likelihood of Approval
GNC-039 is under clinical development by Systimmune and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Danvilostomig by Systimmune for Epithelial Ovarian Cancer: Likelihood of Approval
Danvilostomig is under clinical development by Systimmune and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
BLM-02D1 by Systimmune for Gastrointestinal Tumor: Likelihood of Approval
BLM-02D1 is under clinical development by Systimmune and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase I...
BLM-02D1 by Systimmune for Non-Small Cell Lung Cancer: Likelihood of Approval
BLM-02D1 is under clinical development by Systimmune and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
GNC-039 by Systimmune for High-Grade Glioma: Likelihood of Approval
GNC-039 is under clinical development by Systimmune and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I...